Solid Tumors News

This RSS feed URL is deprecated


This RSS feed URL is deprecated, please update. New URLs can be found in the footers at https://news.google.com/news

Samumed Doses First Patient in Phase 1 Trial of SM08502 for Treatment of Advanced Solid Tumors - GlobeNewswire (press release)



Samumed Doses First Patient in Phase 1 Trial of SM08502 for Treatment of Advanced Solid Tumors 
GlobeNewswire (press release)
This Phase 1, open-label, multi-center, dose-escalation study will evaluate the safety, tolerability and pharmacokinetics (PK) of orally administered SM08502 in subjects with advanced solid tumors. Subjects will receive once-daily dosing of SM08502 for ...

and more » 


Larotrectinib Achieves Over 90% Response in Pediatric Solid Tumors - OncLive



OncLive
 
Larotrectinib Achieves Over 90% Response in Pediatric Solid Tumors 
OncLive
The novel pan-TRK inhibitor larotrectinib (LOXO-101) achieved a 93% response rate in pediatric patients with TRK fusion?positive solid tumors, according to findings from the phase I SCOUT trial presented at the AACR Special Conference on Pediatric ...
Zacks' 7 Best Strong Buys for 2018 Zacks.com

all 39 news articles » 


Scientists discover possible master switch for programming cancer immunotherapy - EurekAlert (press release)



EurekAlert (press release)
 
Scientists discover possible master switch for programming cancer immunotherapy 
EurekAlert (press release)
"Runx3 works on chromosomes inside killer T cells to program genes in way that enables the T cells to accumulate in a solid tumor," said Matthew Pipkin, Ph.D., associate professor in the Department of Immunology and Microbiology on the Florida campus ...

and more » 


Atara Biotherapeutics Announces Updated Positive Interim Results from Multicenter Expanded Access Study of ... - GlobeNewswire (press release)



Atara Biotherapeutics Announces Updated Positive Interim Results from Multicenter Expanded Access Study of ... 
GlobeNewswire (press release)
Atara's most advanced T-cell immunotherapy in development, tabelecleucel, is a potential treatment for patients with rituximab-refractory Epstein-Barr virus (EBV) associated post-transplant lymphoproliferative disorder (EBV+PTLD), as well as other EBV ...
ATARA Biotherapeutics (ATRA) Highlights Updated Positive Interim Results from Multicenter Expanded Access Study ... StreetInsider.com

all 2 news articles » 


Checkpoint blockade in solid tumors and B-cell malignancies, with special consideration of the role of CD200 - Dove Medical Press



Checkpoint blockade in solid tumors and B-cell malignancies, with special consideration of the role of CD200 
Dove Medical Press
Abstract: In the ontogeny of a normal immune response, a series of checkpoints must be overcome to ensure that unwanted and/or harmful self-directed activation responses are avoided. Many of the molecules now known to be active in this overseeing of ...

 


Clinical Data for eFFECTOR Therapeutics' Lead Candidate eFT508 Demonstrates Clinical Activity, Well-Tolerated ... - GlobeNewswire (press release)



Clinical Data for eFFECTOR Therapeutics' Lead Candidate eFT508 Demonstrates Clinical Activity, Well-Tolerated ... 
GlobeNewswire (press release)
The work in lymphoma complements our efforts in solid tumors, which includes an ongoing Phase 2 trial of eFT508 in combination with avelumab in patients with microsatellite stable colorectal cancer.? Patients who experienced either a partial response ...

 


Celgene's Lymphoma Strategy Is Its Biggest Positive, Analyst Says - Benzinga



Benzinga
 
Celgene's Lymphoma Strategy Is Its Biggest Positive, Analyst Says 
Benzinga
Detailing its lymphoma strategy, Celgene said a pivotal study of CELMoD CC-122 is due to begin in 2018, and that the company believes it could have multiple assets by 2022, including Revlimid, CC-122, CC-486 and JCAR07, Harrison said. Celgene plans to ...

 


FDA Approves Foundation Medicine's FoundationOne CDx Diagnostic Test for Solid Tumors - Benzinga



Washington Post
 
FDA Approves Foundation Medicine's FoundationOne CDx Diagnostic Test for Solid Tumors 
Benzinga
Foundation Medicine, Inc. (NASDAQ: FMI) announced that the U.S. Food and Drug Administration (FDA) approved FoundationOne CDx?, the company's comprehensive companion diagnostic test for solid tumors. FoundationOne CDx is intended for use by health ...
FDA approves Foundation Medicine's genomic profiling test for all solid tumors; CMS proposes coverage The Cancer Letter Publications
CMS Proposes Coverage for Next-Gen Precision Medicine Test Health IT Analytics
FDA approves first-of-a-kind test for cancer gene profiling ABC News
Futurism  -Investor's Business Daily  -FDA.gov 
all 61 news articles » 


Targovax announces that first combination trials with ONCOS-102 have passed their initial, planned, independent ... - GlobeNewswire (press release)



Targovax announces that first combination trials with ONCOS-102 have passed their initial, planned, independent ... 
GlobeNewswire (press release)
Oslo, Norway, 11 December 2017 - Targovax ASA (OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target solid tumors, announces that clinical trials investigating ONCOS-102 in the treatment of melanoma and ...

and more » 


Adding precision to multiple myeloma treatments with DNA sequencing: ASH - FierceBiotech



FierceBiotech
 
Adding precision to multiple myeloma treatments with DNA sequencing: ASH 
FierceBiotech
Google subsidiary Verily has also ventured into the liquid biopsy field, launching a startup called Freenome to develop tests for lung cancer, breast cancer and other solid tumors. The Dana-Farber oncologists are planning more studies to further ...

and more »